Table 4.
Comparison of outcome measures across the cohort by multivariate analysis.
| Clinical response at day 7 |
Clinical cure at day 90 |
|||||||
|---|---|---|---|---|---|---|---|---|
| Responder | Non-responder | Total | p value | Responder | Non-responder | Total | p value | |
| Recipient gender | 0·9 | 0.32 | ||||||
| Female | 64 (84%) | 12 (16%) | 76 | 43 (81%) | 10 (19%) | 53 | ||
| Male | 35 (83%) | 7 (17%) | 42 | 23 (72%) | 9 (28%) | 32 | ||
| Stool characteristics | 0·57 | 0·36 | ||||||
| Fresh | 25 (81%) | 6 (19%) | 31 | 21 (84%) | 4 (16%) | 25 | ||
| Frozen | 74 (85%) | 13 (15%) | 87 | 45 (75%) | 15 (25% | 60 | ||
| FMT indication | 0·007 | 0.4 | ||||||
| Recurrence | 64 (91%) | 6 (9%) | 48 | 38 (75%) | 13 (25%) | 51 | ||
| Refractory | 35 (73%) | 13 (27%) | 70 | 28 (82%) | 6 (18%) | 34 | ||
| C. difficile testing result | 0·835 | 0.26 | ||||||
| C. difficile stool toxin EIA positive | 60 (83%) | 12 (17%) | 72 | 44 (81%) | 19 (19%) | 54 | ||
| C. difficile stool toxin EIA negative, stool toxin PCR positive | 39 (85%) | 7 (15%) | 46 | 22 (71%) | 9 (29%) | 31 | ||